Heading into 2026, the pharmaceutical and biotech industries face an operating environment in flux. Each year, we step back to assess how the healthcare landscape is shifting and how pharma is adjusting to compete within it. Key headwinds include U.S. pricing reforms, deglobalization, and reduced innovation funding.